Zydus shares jump 1.2% on securing USFDA approval for manufacturing of Ibuprofen and Famotidine tablets

The ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers (gastric and/or duodenal ulcers) in patients who are taking ibuprofen for those indications. Ibuprofen and famotidine tablets will be produced at Zydus Lifesciences (SEZ), Ahmedabad.

Ibuprofen and Famotidine tablets had annual sales of $3.6 million in the United States (IQVIA MAT December 2024). The group now has 415 approvals and has filed 483 ANDAs since the filing process began in FY 2003-04.

The revenue for the quarter stood at ₹2515.90 crore in Q3FY25 compared to ₹2371.30 crore during the year-ago period. Profit for the quarter ended December 2024 grew by 4.48% to ₹470.60 crores from ₹450.40 crores. Operating Profit reported a decline to ₹726.00 crores from ₹805.90 crores in the corresponding previous quarter.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.